Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Target Price
The average target price of IOBT is 2.4 and suggests 192% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa
Buy
Sell